Ionization

TOMI Environmental Solutions, Inc. Reports First Quarter 2024 Financial Results

Retrieved on: 
Mercoledì, Maggio 15, 2024
Hydrogen, Decontamination, Disinfectant, Restaurant, Infection, Hospital, DARPA, Conference, Police, BIT, Moses Austin, Horsepower, School, Ethylene oxide, International, American Biological Safety Association, Meat, Hydrogen peroxide, Ionization, University, Government, CES, Growth, Science, Webcast

FREDERICK, Md., May 15, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • FREDERICK, Md., May 15, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the first quarter ended March 31, 2024.
  • Financial Results for the three months ended March 31, 2024, compared to March 31, 2023
    Total net revenue was $1,114,000 compared to $1,582,000.
  • TOMI will hold a conference call to discuss first quarter 2024 results at 4:30 p.m.
  • To participate in the call by phone, dial (844) 369-8770 approximately five minutes prior to the scheduled start time and request the "TOMI Environmental Solutions first quarter earnings call."

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
Venerdì, Maggio 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
Venerdì, Maggio 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Multimedia, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series

Retrieved on: 
Martedì, Aprile 30, 2024
Small RNA, Plasmid, Cell, LNP, Spleen, CDMO, Cytoplasm, Liver, Lymph, Toxicity, Ionization, Messenger, Lipid, Dicarboxylic acid

and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.

Key Points: 
  • and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
  • NOF CORPORATION's COATSOME® SS Series offers encapsulation of nucleic acids such as mRNA, siRNA, and pDNA.
  • "This integrated approach, combining lipid chemistries with state-of-the-art development and manufacturing processes provides a well characterized platform for customers developing LNP-based therapies."
  • With this collaboration NOF and Phosphorex create a highly specialized LNP-focused CDMO with unique capabilities," said Yuji Yamamoto, General Manager of Life Science division of NOF CORPORATION.

Photonis' Ion Detection Technology Enables NASA's Key Research of Aurora Phenomenon

Retrieved on: 
Mercoledì, Marzo 13, 2024
Ionization, Temperature, Atmosphere, NASA, Weather

On Nov. 8, NASA's Goddard Flight Center's DISSIPATION mission took flight aboard a suborbital, two-stage sounding rocket launched from the Poker Flats Research Range in Fairbanks, Alaska.

Key Points: 
  • On Nov. 8, NASA's Goddard Flight Center's DISSIPATION mission took flight aboard a suborbital, two-stage sounding rocket launched from the Poker Flats Research Range in Fairbanks, Alaska.
  • The launch occurred shortly after midnight and was timed perfectly with the peak of the aurora that morning, which lasted less than half an hour.
  • This knowledge holds significant implications for enhancing our understanding of aurora formation and improving space weather predictions.
  • "We are excited and honored to contribute our advanced Channeltron(TM) Ion Detection Technology to NASA's DISSIPATION Mission.

TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2023 Financial Results

Retrieved on: 
Lunedì, Aprile 1, 2024
Hydrogen, MGH, Health, Hydrogen peroxide, Sale, Restaurant, Ionization, RELX, International, Webcast, Education, Harvard University, Food industry, GPO, Holiday, Global Biorisk Advisory Council, Academic Medical Center (Amsterdam), Police, Meat, Completion, Transport, Decontamination, Medication, AALAS, American Biological Safety Association, Research, Hospital, Food, ISSA, BIT, CES, Disinfectant, Conference, Horsepower, Growth, Assistant, MIT, Executive, School, Infection, DARPA, Environmental Health (journal), Raymond Castellani, Health care

FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.

Key Points: 
  • FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.
  • Financial Results for the year ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $7,355,000 compared to $8,338,000.
  • Financial Results for the three months ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $1,528,000 compared to $2,812,000.
  • TOMI will hold a conference call to discuss Fourth Quarter and year end 2023 results at 4:30 p.m.

TOMI Environmental Announces Additional iHP Custom Engineered System Installation Contracted for California

Retrieved on: 
Giovedì, Febbraio 29, 2024
Hydrogen, ISO, DARPA, Hospital, Restaurant, Hydrogen peroxide, Disinfectant, Annual report, ISPE, Growth, GMP, Ionization, Horsepower, Meat, School, COVID-19, Automation, Decontamination, CES, Police, Laboratory

FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company.

Key Points: 
  • FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company.
  • The contracted iHP Custom Engineered System (CES) is valued at approximately $600,000.
  • Following a presentation by Dr. Halden Shane, CEO of TOMI, at an ISPE event hosted by Avid Bioservices, the contractors recognized the benefits of the automated iHP Custom Engineered System showcased in Avid's new facility and brought SteraMist iHP to the customer as an option.
  • Shane, COO of TOMI states, “We’re pleased to announce this new CES contract and look forward to continuing our growth momentum.

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Febbraio 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.